September 2024 - Portal Instruments welcomes Matt Regan to its Board of Directors. Regan has held extensive leadership roles for prominent pharmaceutical companies such as Abbvie, Novo Nordisk and Micreos.
Matt Regan, a seasoned leader in the healthcare and life sciences industry, has recently joined the Board of Directors at Portal Instruments. This strategic move brings valuable expertise to Portal, a company focused on revolutionizing drug delivery through its innovative needle-free injection technology.
Regan's addition to the board underscores Portal Instruments' commitment to innovation and growth. His pharmaceutical insights and leadership will play a crucial role in shaping the company's future as it continues to advance its technology.
March 27th, 2020 Portal’s mission is to improve the experience for patients on life-changing therapies and that mission remains in the forefront of our minds as we, like everyone else, navigate these unchartered waters with the COVID-19 pandemic.
Portal Instruments is pleased to be showcasing its latest drug delivery platform at the LSI conference in California next week. CEO Patrick Anquetil will be available for personalized demonstrations and in-depth discussions about the technology's benefits and potential impact.
September 28, 2021 - Cambridge, MA Portal Instruments, developer of the PRIME needle-free drug delivery platform, announced that a new clinical study demonstrating patient preference for PRIME needle-free injections was published this month in the journal Drug Delivery.
Please fill out the details below and we will get back to you shortly.